LHX3 is an early stage and radiosensitivity prognostic biomarker in lung adenocarcinoma.

Authors: Lin X, Li Y, Wang J, Han F, Lu S, Wang Y, Luo W, Zhang M Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. We previously identified LHX3 as a new preferentially expressed gene in NSCLC. In the present study, we sought to determine its expression, the clinical relevance and the functional roles in NSCLC. LHX3 expression is sharply increased in carcinoma tissues compared to non-carcinoma tissues. Relational analysis reveals a significant association between LHX3 expression and clinical stage (n=172, p=0.032) or radiotherapy (n=167, p=0.022) of patients. LHX3 expression is much higher in the patients at advanced stages (stage III-IV) than in the patients at early stages (stage I-II, p=0.0304), and LHX3 expression is remarkably increased in ...

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uTebil
via IFTTT